Study of IV CBL0137 in Previously Treated Hematological Subjects
Status:
Terminated
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and
cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics,
and antitumor activity of intravenously (IV) administered CBL0137 in participants with
previously treated hematological malignancies.